http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013113723-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8128 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 |
| filingDate | 2011-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013113723-A |
| titleOfInvention | HYBRID POLYPEPTIDE WITH A SERPIN FINGER |
| abstract | 1. A hybrid polypeptide containing the polypeptide is a serpin domain and a biologically active polypeptide. 2. The hybrid polypeptide according to claim 1, characterized in that the amino acid residue at position 2 of the amino acid sequence of the polypeptide, the serpin domain, is glutamic acid. The hybrid polypeptide according to claim 1, characterized in that the polypeptide is a serpine domain has an amino acid sequence of 8 to 14 amino acid residues in length. The hybrid polypeptide according to claim 1, characterized in that the biologically active polypeptide is a polypeptide - an HIV fusion inhibitor. The hybrid polypeptide according to claim 1, characterized in that the amino acid sequence of the polypeptide-serpin domain is selected from TEAAGAMFLEAIVM (SEQ ID NO: 03), TEAAGAMFFEAIPM (SEQ ID NO: 05), SEAAASTAVVIA (SEQ ID NO: 07), TEAAGATAVVIA (SEQ ID NO: 08) or SEAAASMFLEAI (SEQ ID NO: 11) .6. The hybrid polypeptide according to claim 5, characterized in that the amino acid sequence of the polypeptide is the serine domain of SEAAASTAVVIA (SEQ ID NO: 07) or SEAAASMFLEAI (SEQ ID NO: 11). The hybrid polypeptide according to claim 1, characterized in that the hybrid polypeptide contains a polypeptide — a peptide linker (bridge) between the polypeptide — the serpine domain and a biologically active polypeptide with the amino acid sequence GGSGG (SEQ ID NO: 12) .8. The hybrid polypeptide according to claim 4, characterized in that the amino acid sequence of the HIV fusion inhibitor polypeptide is MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF (SEQ ID NO: 13) .9. The protein complex of the hybrid polypeptide according to any one of paragraphs. 1 - 8 and serpine. 10. The protein complex according to claim 9, characterized in that the serpine is selected from alpha1-antitrypsin and antithrombin. A hybrid polypeptide according to any and |
| priorityDate | 2010-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.